Saxenda is dead and nobody is saying it
No recall, no safety event. A billion-dollar drug lost its prescriber base in under two years.
Why GLP-1s affect alcohol craving
The receptor-level story behind a side effect that is quietly reframing addiction research.
Why telehealth is winning the distribution war
Manufacturers now sell through the channel directly. Regulation has not caught up.
What the GIP receptor does that we underestimated
Half of what tirzepatide does runs through a receptor the field barely discusses.